Financials

  • Market Capitalization 325.92 M
  • Employee 88
  • Founded 1994
  • CEO Craig A Tooman
  • Website www.silence-therapeutics.com
  • Headquarter United Kingdom
  • FIGI BBG00WVTHPN2
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-9.65
ratio cours/chiffre d'affaires
1 541.15

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

Nouvelles